Treatment for Alzheimer's diseases
https://doi.org/10.14412/2074-2711-2015-3-80-85
Abstract
The paper gives an update on the epidemiology, etiology, pathogenesis, prevention, and treatment of Alzheimer's disease (AD). It points out the role of acetylcholine and glutamatergic components of neurotransmission in the pathogenesis of the disease, as well as their interactions, which is important to keep in mind to have a potentiated response to therapy that includes both these components. Different approaches to AD therapy are considered on the basis of the current ideas on the pathogenetic mechanisms of a degenerative process and with regard to the clinical features of the disease (the nature of the psychopathological symptoms of the disease and its stage). Particular emphasis is placed on compensatory therapy for deficient cholinergic and glutamatergic neurotransmission. Whether psychopharmacological agents may be used and psychotherapeutic work with the relatives of patients with AD should be done are also highlighted. Data on the efficiency of replacement therapy for different dementia stages, which promotes a delay in degenerative processes and a definite stabilization of the mental status, are presented.
About the Authors
Nina Arkadyevna Tyuvina
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Psychiatry and Narcology,
11, Rossolimo St., Build. 9, Moscow 119021
V. V. Balabanova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Department of Psychiatry and Narcology,
11, Rossolimo St., Build. 9, Moscow 119021
References
1. Hebert LE, Scherr PA, Beckett LA, et al. Age specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354-9.
2. Гаврилова СИ, Колыхалов ИВ, Милопольская ИМ и др. Танакан в лечении начальных проявлений церебрально-сосудистой недостаточности. Клиническая геронтология 1995;(4):22-3. [Gavrilova SI, Kolykhalov IV, Milopol'skaya I, et al. Tanakan in the treatment of initial manifestations of cerebrovascular insufficiency. Klinicheskaya gerontologiya. 1995; (4):22-3. (In Russ.)].
3. Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEMPrevalence Research Group. Ann Neurol. 1991 Sep;30(3):381-90.
4. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. Review. J Neurol Sci. 2007 Jun 15;257(1-2):80-7. Epub 2007 Feb 26.
5. Штернберг ЭЯ. Клиника деменций пресенильного возраста. Москва: Медицина; 1967. 247с. [Shternberg EYa. Klinika dementsii presenil'nogo vozrasta [Clinic of dementia in presenile age]. Moscow: Meditsina; 1967. 247s.]
6. Wang GD, Lai DJ, Burau KD, Du XL. Potential gains in life expectancy from reducing heart disease, cancer, Alzheimer's disease or HIV/AIDS a major causes of death in the USA. Public Health. 2013 Apr;127(4):348-56. doi: 10.1016/j.puhe.2013.01.005. Epub 2013 Mar 16.
7. Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol. 2005 Feb;62(2):192-5.
8. Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13. [Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2011-159
9. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012 Nov 15;322 (1-2):141-7. doi: 10.1016/j.jns.2012.07.032. Epub 2012 Aug 11.
10. Li G, Rhew IC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc. 2007 Aug;55(8):1161-7.
11. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64-74.
12. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011 May;12(5):e426-37. doi: 10.1111/j.1467-789X.2010.00825.x. Epub 2011 Feb 23.
13. Ho L, Zhao W, Dams-O'Connor K, et al. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential «predisposition» factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis. 2012;31(2):301-13. doi: 10.3233/JAD-2012-120598.
14. Tan ZS, Vasan RS. Thyroid function and Alzheimer's disease. J Alzheimers Dis. 2009;16(3):503-7. doi: 10.3233/JAD-2009-0991.
15. Wu KY, Hsiao IT, Chen CS, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidence on positron emission tomography. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):714-22.
16. Ptok U, Papassotiropoulos A, Maier W, Heun R. Advanced parental age: a risk factor for Alzheimer's disease or depression in the elderly? Int Psychogeriatr. 2000 Dec;12(4):445-51.
17. Pardon MC, Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neurosci Biobehav Rev. 2008 Aug;32(6):1103-20. doi: 10.1016/j.neubiorev.2008.03.005. Epub 2008 Mar 18.
18. Foster PP, Rosenblatt KP, Kuljis RO. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. Front Neurol. 2011 May 6;2:28. doi: 10.3389/fneur.2011.00028.eCollection 2011.
19. Paillard T, Rolland Y, de Souto Barreto P. Protective Effects of Physical Exercise in Alzheimer's Disease and Parkinson's Disease: A Narrative Review. J Clin Neurol. 2015 Jul;11(3):212-9. doi: 10.3988/jcn.2015.11.3.212.
20. Chakrabarti M, Haque A, Banik NL, et al. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res Bull. 2014 Oct;109:22-31. doi: 10.1016/j.brainresbull.2014.09.004. Epub 2014 Sep 20.
21. Enciu AM, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.
22. Cho H, Kim C, Kim HJ, et al. Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. Eur J Neurol. 2015 Aug 11. doi: 10.1111/ene.12816. [Epub ahead of print]
23. Panza F, Frisardi V, Seripa D, et al. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? Review. Int J Geriatr Psychiatry. 2012 Dec;27(12):1218-38. doi: 10.1002/gps.3772. Epub 2012 Mar 7.
24. Solfrizzi V, Panza F, Frisardi V, et al. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother. 2011 May;11(5):677-708. doi: 10.1586/ern.11.56.
25. Plassman BL, Breitner JC. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. J Am Geriatr Soc. 1996 Oct;44(10):1242-50.
26. Sleegers K, Van Duijn CM. Alzheimer's disease: genes, pathogenesis and risk prediction. Community Genet. 2001 Jun;4(4):197-203.
27. Wragg M, Hutton M, Talbot C. The Alzheimer's Disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet. 1996 Feb 24;347(9000):509-12.
28. Bohm C, Chen F, Sevalle J, et al.Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015;66(Pt A):3-11. doi: 10.1016/j.mcn.2015.02.016. Epub 2015 Mar 4.
29. Zekonyte J, Sakai K, Nicoll JA, et al. Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: Relevance to accumulation of Aβ in Alzheimer's disease. Biochim Biophys Acta. 2015 Aug 29. pii: S0925-4439(15)00262-8. doi: 10.1016/j.bbadis.2015.08.025. [Epub ahead of print]
30. Бойко ЕР, Канева АМ. Апопротеин Е и его значение в клинической физиологии. Успехи физиологических наук. 2009;40(1):3-15. [Boiko ER, Kaneva AM. Apoprotein E and its value in clinical physiology. Uspekhi fiziologicheskikh nauk. 2009;40(1):3-15. (In Russ.)].
31. Yamaguchi H. Amyloid Morphology and Pathology of Alzheimer's Disease. In: Molecular Biology of Alzheimer's Desease. Genes and Mechanisms Involved in Amyloid Generation. Haas S, editor. Harwood academic publishers;1998. P. 2-14.
32. Braak H, Braak E. Pattern of cortical lesions in Alzheimer's disease. In Alzheimer's disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B , Nishimura T, Takeda M, Wisniewski HM, editors. England: Wiley; 1997. P. 227-37.
33. Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain. Acta Neuropathol. 1989;77(3):314-9.
34. Wong PC, Savonenko A, Li T, Price DL. Neurobiology of Alzheimer's Disease. In: Basic Neurochemistry, Eighth Edition: Principles of Molecular, Cellular, and Medical Neurobiology. Brady S, Siegel G, Alberts RW, Price D, editors. Amsterdam, London etc.: Academic Press; 2012. P. 815-28.
35. Selkoe DJ. Alzheimer's Disease. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition). Rosenberg RN, Pascual JM, editors. Elsevier; 2015. P. 753-68.
36. Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem. 1983 Feb;40(2):503-9.
37. Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. Epub 2003 Jun 12.
38. Selkoe DJ, Landsbury J. Biochemitry of Alzheimer's and prion diseases. In: Basic Neurochemistry. Molecular, Cellular and Medical Asects. 6-th ed. Siegel GJ, Agranoff BW, Alberts RW, Fisher SK, Uhler MD, editors. Philadelphia: Lippincott-Raven; 1999. P. 949-70.
39. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5.
40. Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Dis Extra. 2015 Apr 10;5(1):135-46. doi: 10.1159/000375527.
41. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.
42. Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.
43. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.
44. Miller LJ. The use of cognitive enhancers in behavioural disturbances of Alzheimer's disease. Consult Pharm. 2007 Sep;22(9):754-62.
45. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.
46. Гаврилова СИ, Герасимов НП, Калын ЯБ и др. Долговременные эффекты глутаматергической терапии болезни Альцгеймера на стадии умеренно-тяжелой и тяжелой деменции (Результаты 26-недельного сравнительного клинического исследования в параллельных группах больных: леченных акатинолом мемантином и получавших симптоматическую нейролептическую терапию). Социальная и клиническая психиатрия. 2006; 16(1):32-7. [Gavrilova SI, Gerasimov NP, Kalyn YaB i dr. Long-term effects of glutamatergic therapy for Alzheimer's disease at the stage of moderately severe and severe dementia (Results of a 26-week comparative clinical study in parallel groups patients: treated with akatinol memantine and neuroleptic treated with symptomatic therapy). Sotsial'naya i klinicheskaya psikhiatriya. 2006; 16(1):32-7. (In Russ.)].
47. Grossberg GT, Manes F, Allegri RF, et al.The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.
48. Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.
49. Вознесенская ТГ. Акатинол в лечении некогнитивных нервно-психических расстройств при нейрогериатрических заболеваниях. Неврология, нейропсихиатрия, психосоматика. 2012;4(Спецвыпуск 2):11-7. [Voznesenskaya TG. Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(S2):11-7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-2503
50. Reisberg B, Doody R, Stö ffler A, et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.
51. Вознесенская ТГ, Медведева АВ, Яхно НН. Некогнитивные нейропсихические расстройства при болезни Альцгеймера и их коррекция. Неврологический журнал. 2010;15(4):18-25. [Voznesenskaya TG, Medvedeva AV, Yakhno NN. Non-cognitive neuropsychiatric disorders in Alzheimer's disease and their correction. Nevrologicheskii zhurnal. 2010;15(4):18-25. (In Russ.)].
52. Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioural and psychological symptoms related to dementia – a systematic meta-analyses. Ann Pharmacother. 2008 Jan;42(1):32-8. Epub 2007 Dec 4.
53. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe AD by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 May;23(5):537-45.
54. Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderate severe AD: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8.
55. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7. doi: 10.1136/jnnp.2008.158964. Epub 2009 Feb 9.
56. Rammes G, Danysz W, Parsons CG. Pharmacodynamics of Memantine: An Update. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.
57. Fan P. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br J Pharmacol. 1994 Jul;112(3):741-4.
58. Rammes G, Eisensamer B, Ferrari U, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry. 2004 Sep;9(9):846-58, 818.
59. Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.
60. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA. 2014 Jun 10;111(23):8649-54. doi: 10.1073/pnas.1323920111. Epub 2014 May 27.
61. Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl). 1993;112(1 Suppl):S68-75.
62. Annweiler C, Herrmann FR, Fantino B, et al. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012 Sep;25(3):121-7. doi: 10.1097/WNN.0b013e31826df647.
63. Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):627-36.
64. Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009 Feb;9(1):24-30. doi: 10.1016/j.coph.2008.12.006. Epub 2009 Jan 20.
65. Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2010 Jul;11(10):1765-71. doi: 10.1517/14656566.2010.493874.
66. Shao ZQ. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. Int J Clin Exp Med. 2015 Feb 15;8(2):2944-8. eCollection 2015.
67. Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9.
Review
For citations:
Tyuvina N.A., Balabanova V.V. Treatment for Alzheimer's diseases. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(3):80-85. (In Russ.) https://doi.org/10.14412/2074-2711-2015-3-80-85
Views: 2060
Email this article 